Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Univariate and multivariate analyses for survival of adenocarcinoma patients

From: Prognostic significance of peripheral CD8+CD28+ and CD8+CD28− T cells in advanced non-small cell lung cancer patients treated with chemo(radio)therapy

Variables Overall survival Progression-free survival
HR (95% CI) P HR (95% CI) P
A (univariate)
 Gender
  Male 1.88 (0.89–3.97) 0.094 2.16 (1.10–4.23) 0.025
  Female 1   1  
 Age (years)
  ≥ 60 1.23 (0.60–2.54) 0.565 1.12 (0.58–2.13) 0.731
  < 60 1   1  
 Smoking status
  Ever smokers 1.73 (0.84–3.55) 0.136 1.60 (0.84–3.04) 0.147
  Never smokers 1   1  
 cStage
  IV 1.05 (0.25–4.45) 0.940 0.76 (0.23–2.49) 0.658
  III 1   1  
 Tumor differentiation
  Poor 1.90 (0.88–4.11) 0.101 1.75 (0.89–3.45) 0.103
  Well/moderate 1   1  
 Performance status
  1–2 1.68 (0.64–4.41) 0.291 1.97 (0.82–4.73) 0.129
  0 1   1  
B 0.99 (0.92–1.07) 0.818 0.93 (0.86–1.06) 0.677
NK 1.01 (0.96–1.05) 0.892 0.96 (0.91–1.02) 0.645
NKT 0.87 (0.58–1.09) 0.583 0.68 (0.36–1.07) 0.328
γδT 0.94 (0.85–1.05) 0.298 0.95 (0.86–1.04) 0.295
CD8+CD28+ 0.52 (0.25–0.92) 0.013 0.59 (0.29–0.96) 0.016
CD8+CD28− 0.93 (0.79–1.12) 0.349 0.98 (0.95–1.02) 0.314
CD28+/CD28− 1.08 (0.69–1.68) 0.735 1.00 (0.68–1.47) 0.991
CD4+CD25hi 1.57 (0.88–2.46) 0.153 1.96 (1.22–2.81) 0.011
B (multivariate)
 Gender 1.92 (0.82–4.49) 0.133 2.12 (0.99–4.57) 0.055
 CD8+CD28+ 0.51 (0.30–0.89) 0.021 0.66 (0.37–0.93) 0.038
 CD4+CD25hi 1.53 (1.19–1.97) 0.031
  1. P-values for multivariate analyses are adjusted. The HR and 95% CI were reported for 1 SD increase for immune cells